PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
CNS Spectr. Author manuscript; available in PMC 2010 August 25.
Published in final edited form as:
CNS Spectr. 2009 April; 14(4): 175–176.
PMCID: PMC2928142
NIHMSID: NIHMS229422

Selective Benefit of Donepezil on Oral Naming in Alzheimer’s Disease in Men Compared to Women

To the Editor:

Donepezil is a widely prescribed treatment for patients with probable Alzheimer’s disease. Although it is accepted that donepezil can slow the decline of cognitive functioning in various stages of Alzheimer’s disease,1 sex differences affecting its efficacy are often omitted from a prescribing rationale.

We examined data from a larger study testing the effect of donepezil on cognitive functioning as well as awareness of cognitive deficits in probable Alzheimer’s disease (12 participants, [7 women; 5 men] diagnosed with probable Alzheimer’s disease2). All subjects were neuropsychologically evaluated with the Mini-Mental State (MMSE),3 the Boston Naming Test (BNT),4 and the Hopkins Verbal Learning Test (HVLT).5

Following a baseline evaluation, subjects were randomized to one of two double-blind crossover groups. In Group 1, 7 subjects (5 women; 2 men) received donepezil 5 mg/day for 2 months, and then received placebo for 2 months. In Group 2, 5 subjects (2 women; 3 men) received placebo for 2 months, and then donepezil 5 mg/day for 2 months. At the end of the four-month crossover treatment period, all subjects returned for neuropsychological re-assessment.

A therapeutic effect of donepezil on cognition in probable Alzheimer’s disease was previously reported in studies examining aggregate memory, orientation, attention, reasoning, language and praxis performance.1,6 This previous research suggested that global cognitive functioning, including naming and language indices improved in probable Alzheimer’s disease patients taking this medication.1 Data from our small group confirmed a specific therapeutic effect on donepezil on picture naming performance on the BNT4 (mean on=71.9, SD 21.81; mean off=64.8±21.52). Within-subjects repeated-measures ANOVA revealed significant main effect of drug, F(1,11)=17.405, P<.01, partial eta2=0.64). However, we also observed significant interaction of drug and gender in performance on the BNT (mean male on=75.3±23.76; mean male off=61.2±25.13; mean female on=69.5±21.89; mean female off=67.3±20.23; F(1,11)=9.191, P<.05, partial eta2=0.48.) (Table 1).

Table 1
Performance on Neuropsychological Tests for Probable Alzheimer’s Disease Participants in the Current Study*

Whether severity accounts for the sex difference in this study is unclear. Men may have had more severe symptoms, indicated by lower MMSE scores (men’s mean=18.4±7.127; women’s mean=21.714±6.237), but since men actually performed better on the BNT and the HVLT at baseline, we do not think this explains the sex difference in oral naming response to donepezil.

Cholinesterase inhibitor treatment, including donepezil, has been reported to be more effective in men in previous studies of humans with probable Alzheimer’s disease,7,8 and in animal models of memory disorders.1,2

In a short-term (three-month) treatment study MacGowan and colleagues8 found that performance on MMSE was more stable or positively affected by men on tacrine (76%) than women (52%). In a logistic regression, sex emerged as the only significant predictor of response to cholinesterase inhibitor treatment with a 73% greater response rate for men than women.8 Animal studies have indicated various reasons why cholinesterase inhibitors may be more successful in males than females, including the presence of testosterone, synaptic protein content, acteylcholinesterase activity, levels of acetylecholine, brain atrophy rates, the presence of the APOE *E4 alleles or different optimal dosage levels.7,8

If donepezil and other cholinesterase inhibitors are more effective in men than they are in women, this is of obvious importance in disorders like probable Alzheimer’s disease, of which the majority of sufferers are female. It may also be of relevance, however, for treatment of other cognitive dysfunction, for example the treatment of memory disorders due to brain injury9 and post-stroke aphasia.10 A difference in expected therapeutic effect by sex may indicate that different dosing regiments should be considered for female compared with male patients for memory and cognitive symptoms. Future research should also address whether sex differences may differently affect distinct cognitive domains, since sex differences in therapeutic effect may interact with underlying population differences in cognitive skills such has verbal memory or visuospatial performance.

Acknowledgments

We thank Drs. Kenneth Heilman and Paul Eslinger for assisting with the conception and operations, respectively, of that study. Dr. Noel Ballentine screened and referred patients to that study. Lynn Leidig, Kerri Hansell, Keri Muniz and Chris Spofford collected subject neuropsychological data. Patient testing was performed in the Penn State General Clinical Research Center (NIH/NCRR C06 RR016499/M01 RR010732).

Footnotes

Disclosure: Data reported was collected as part of a study of cognitive anosognosia in Alzheimer Disease, supported by the Alzheimer Disease Association (PRG-99-1702) and by medication and pharmacy fees from Eisai and Pfizer. Data analyis and manuscript preparation was supported by the Henry H. Kessler Foundation and the National Institutes of Health (NINDS; K02 NS47099 awarded to Dr. Barrett).

REFERENCES

1. Rogers SL, Farlow MR, Doody RS, et al. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer’s disease. Neurology. 1998;50:136–145. [PubMed]
2. Barrett AM, Eslinger PJ, Ballentine NH, et al. Unawareness of cognitive deficit (cognitive anosognosia) in probable AD and control subjects. Neurology. 2005;64:693–699. [PubMed]
3. Folstein MF, Folstein SE, McHugh PR. Mini-Mental State: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189–198. [PubMed]
4. Kaplan E, Goodglass H, Weintraub S. Boston Naming Test. Media, Pennslyvania: Williams & Wilkins; 1983.
5. Brandt J. The Hopkins Verbal Learning Test: development of a new memory test with six equivalent forms. Clin Neuropsychol. 1991;5:125–142.
6. Takeda A, Loveman A, Clegg J, et al. A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer’s disease. Int J Geriatr Psychiatry. 2006;21:17–28. [PubMed]
7. Haywood WM, Mukaetova-Ladinska EB. Sex influences on cholinesterase inhibitor treatment in elderly individuals with Alzheimer’s Disease. Am J Geriatr Pharmacother. 2006;4:273–286. [PubMed]
8. MacGowan SH, Wilcock GK, Scott M. Effect of sex and apolipoprotein E genotype on response to anthicholinesterase therapy in Alzheimer’s disease. Int J Geriatr Psychiatry. 1998;13:625–630. [PubMed]
9. King KA, Hough MS, Walker MM, et al. Mild traumatic brain injury: Effects on naming in word retrieval and discourse. Brain Inj. 2006;20:725–732. [PubMed]
10. Klein RB, Martin LA. Can drug therapies improve language functions of individuals with aphasia? A review of the evidence. Semin Speech Lang. 2004;25:193–220. [PubMed]